Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Suzhou MedicalSystem Technology Co., Ltd., established in Suzhou, China, in 2005, is a company dedicated to developing and implementing advanced clinical information technology and digital hospital management solutions throughout China. Their product portfolio primarily features the "DoCare" suite of systems: The DoCare anesthesia clinical information system is tailored for the perioperative environment, offering an integrated platform that streamlines, digitalizes, automates, and intelligently manages clinical workflows during surgical procedures. The DoCare intensive auxiliary diagnosis clinical information system focuses on extracting and scientifically analyzing treatment data from ICU patients. It integrates diverse medical information, including treatment details, inspection results, nursing records, and doctor's orders, to support diagnosis and decision-making. The DoCare operative medical behavior management system provides intelligent oversight for operating room resources and staff activities. The DoCare emergency clinical information system offers comprehensive management for emergency care services. This spans the entire patient journey, from pre-hospital first aid and initial triage to active rescue, emergency observation, specialized emergency operating rooms and ICUs, and final patient outcomes. The DoCare pre-hospital first aid clinical information system creates a unified digital service platform connecting emergency command centers, medical personnel (doctors, nurses, visiting staff), and patients for pre-hospital care. Beyond these core offerings, the company also provides specialized "smart" solutions for operating theaters (OT), intensive care units (ICUs), and emergency departments. Additionally, their smart specialty solutions include systems for laminar airflow rooms, clinical pathways, mobile nursing information, and central sterile supply department (CSSD) management.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA